Ω3 PUFAs are incorporated into the intestinal mucosa of patients with inflammatory bowel disease (IBD) receiving supplemental fish oil and result in anti-inflammatory activity with reduced leukotriene B (LTB4) production by neutrophils and the intestinal mucosa, reduced production of prostaglandin E2 (PGE2) and thromboxane B2 (TXB2) by the intestinal mucosa and reduced PGE-2 and interferon gamma (IFN-γ) production by monocytes [7,8,9,10,11]. This evidence concerns the gene IFNG and inflammatory bowel disease.